DDInter1042 DDInter31
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Adenosine {u} (Compound) resembles {v} (Compound) Azacitidine
Adenosine {u} (Compound) resembles {v} (Compound) Nelarabine
Adenosine {u} (Compound) binds {v} (Gene) ADORA2B
Adenosine {u} (Compound) is included by {v} (Pharmacologic Class) Adenosine Receptor Agonists
Adenosine {u} (Compound) downregulates {v} (Gene) KIF14
Adenosine {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Adenosine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cilostazol
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Adenosine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Adenosine (Compound) resembles Azacitidine (Compound)
Adenosine (Compound) resembles Nelarabine (Compound)
Adenosine (Compound) binds ADORA2B (Gene)
Adenosine (Compound) is included by Adenosine Receptor Agonists (Pharmacologic Class)
Adenosine (Compound) downregulates KIF14 (Gene)
Adenosine (Compound) causes Atrioventricular block (Side Effect)
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Adenosine may lead to a major life threatening interaction when taken with Ribociclib